8-K: Supernus Boosts Executive Compensation, Awards 2025 Bonuses

Supernus Pharmaceuticals, Inc. announced modifications to its executive officers' compensation, including salary increases, 2025 bonuses, and equity awards, effective January 1, 2026.

Summary

• The Compensation Committee and Board of Directors approved modifications to executive officer compensation on February 18, 2026, with salary increases effective January 1, 2026.
• President and CEO Jack A. Khattar's annual base salary increased from $1,036,000 to $1,067,100, and he was awarded a 2025 bonus of $846,930, 341,610 stock options, and 204,966 performance share units (PSUs). His 2026 bonus target remains 75% of base salary.
• SVP and CFO Timothy C. Dec's annual base salary increased from $504,900 to $525,100, and he received a 2025 bonus of $233,894, 17,500 stock options, 3,000 restricted stock units (RSUs), and 3,500 PSUs. His 2026 bonus target remains 45% of base salary.
• SVP, Intellectual Property and CSO Padmanabh P. Bhatt, Ph.D.'s annual base salary increased from $455,900 to $471,900, and he was awarded a 2025 bonus of $168,182, 13,500 stock options, 3,000 RSUs, and 3,500 PSUs. His 2026 bonus target remains 35% of base salary.
• SVP and CMO Jonathan Rubin, M.D.'s annual base salary increased from $485,100 to $504,500, and he received a 2025 bonus of $197,843, 13,500 stock options, 3,000 RSUs, and 3,500 PSUs. His 2026 bonus target remains 40% of base salary.
• SVP, Quality, GMP Operations and IT Frank Mottola's annual base salary increased from $412,500 to $429,000, and he was awarded a 2025 bonus of $173,910, 13,500 stock options, 3,000 RSUs, and 3,500 PSUs. His 2026 bonus target remains 40% of base salary.
• These compensation adjustments were based on the Committee's annual review and are consistent with the company's industry peer group, as advised by Aon plc.
• Stock option grants and RSU awards will vest annually in equal increments over a four-year period, with an exercise price of $50.20 per share for options, based on the closing price on February 18, 2026.
• PSU awards vest based on the achievement of specified performance goals, as determined by the Committee, and require continuous employment.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive development reflecting competitive executive compensation practices and a commitment to performance-based incentives, which can align management interests with shareholder value. It does not indicate any significant operational or financial changes.

Positives

• Executive compensation adjustments align with industry peer group standards, as advised by an independent compensation consultant (Aon plc).
• The inclusion of performance share units (PSUs) links a significant portion of executive compensation to the achievement of specific company performance goals, potentially aligning management incentives with shareholder interests.
• The routine nature of these compensation reviews indicates stable corporate governance practices.

Risks

• The vesting of performance share units (PSUs) is contingent upon the achievement of specified performance goals, meaning executives may not realize the full value of these awards if targets are not met.
• The value of stock options and RSUs is subject to future stock price performance, introducing market risk for the executives' equity compensation.

Future Outlook

The future outlook includes the vesting of performance share units (PSUs) based on the achievement of specified performance goals, which will be certified by the Compensation Committee. Additionally, 2026 bonus targets have been set for executive officers, indicating ongoing performance incentives.

Management Comments

• "These increases were the result of the Committee's annual compensation review for executive officers."
• "These increases in annual base salary became effective as of January 1, 2026, and are consistent with the Company's industry peer group and were recommended to the Committee by the Human Capital Solutions practice of Aon plc, its independent compensation consulting company."

Industry Context

StockSavvy.ai notes that competitive executive compensation packages are crucial in the pharmaceutical industry to attract and retain top talent, especially given the long development cycles, high R&D costs, and regulatory complexities inherent in drug discovery and commercialization. The use of performance-based equity awards is a common strategy to align executive incentives with long-term shareholder value creation in this sector.

Comparison to Industry Standards

• StockSavvy.ai notes that the company explicitly states these increases are "consistent with the Company's industry peer group" and were recommended by Aon plc, an independent compensation consulting company. This suggests the compensation structure aligns with broader industry practices for similar-sized pharmaceutical companies, which often utilize a mix of base salary, annual cash bonuses, and long-term equity incentives (like stock options, RSUs, and PSUs) to reward and retain executives.
• The four-year vesting period for stock options and RSUs is a common practice in the pharmaceutical and biotech industries, designed to encourage long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value through performance-based equity awards, balanced against increased compensation expense.
• Employees: May signal a competitive compensation philosophy within the company, potentially impacting morale and retention across the organization.
• Executive Officers: Direct impact on their total compensation, including base salary, cash bonuses, and long-term equity incentives, tied to both time and performance.

Next Steps

• The Compensation Committee will make determinations and certify the achievement of performance goals for the PSUs, leading to their vesting.

Key Dates

Recommendation

This 8-K filing details routine executive compensation adjustments, including salary increases and performance-based equity awards. While these reflect standard corporate governance and competitive practices, they do not present new material information regarding the company's operational performance, strategic direction, or financial outlook that would warrant a change in investment recommendation based solely on this report. The information is largely administrative and expected.

Keywords

Supernus Pharmaceuticals, executive compensation, salary increase, stock options, performance share units, restricted stock units, corporate governance, pharmaceuticals, biotech, SEC filing